Hematologic Malignancy
Diffuse Large B-Cell Lymphoma
CI-CAN-00005107DLBCLExplore in graph →
Hematologic355 active trials5 approved drugs19 evidence items
- NCIt
- C8851
- DOID
- 0050745
- Other
- 4 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005107DLBCLExplore in graph →
Clinical trials
1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04231747 | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 | 24 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 2 | May 20, 2024 | clinicaltrials |
| NCT04164368 | Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients | completed | Phase 2 | 67 | Fudan UniversityOTHER | 1 | May 13, 2024 |
| clinicaltrials |
| NCT04438005 | A Study of ICP-022 in Patients With R/R DLBCL(DLBCL) | completed | Phase 2 | 3 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | May 13, 2024 | clinicaltrials |
| NCT03892044 | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | completed | Phase 1 | 7 | David Bond, MDOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06392763 | Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data | completed | — | 602 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT02445248 | Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients(JULIET) | completed | Phase 2 | 115 | Novartis PharmaceuticalsINDUSTRY | 10 | Apr 18, 2024 | clinicaltrials |
| NCT03610061 | A Trial of Radiotherapy and Durvalumab in DLBCL and FL(RaDD) | completed | Phase 1 | 34 | Austin HealthOTHER_GOV | 1 | Apr 12, 2024 | clinicaltrials |
| NCT00799513 | Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma(RV-NHL-PI351) | completed | Phase 2 | 48 | IRCCS San RaffaeleOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | completed | Phase 1 / Phase 2 | 400 | Epizyme, Inc.INDUSTRY | 10 | Mar 26, 2024 | clinicaltrials |
| NCT02636322 | Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT02926833 | Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)(ZUMA-6) | completed | Phase 1 / Phase 2 | 37 | Kite, A Gilead CompanyINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04695366 | The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell Lymphoma | completed | — | 250 | Herlev HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06271369 | Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study. | completed | — | 613 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04858568 | Immune Responses to COVID-19 Vaccination in Lymphoma Patients(PROSECO) | completed | — | 592 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT02658968 | Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | completed | Phase 1 | 18 | Nordic NanovectorINDUSTRY | 5 | Jan 16, 2024 | clinicaltrials |
| NCT03833180 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | completed | Phase 1 | 91 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03399513 | Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma(R-CHOEP-brut) | completed | Phase 2 | 40 | University Hospital MuensterOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04361279 | A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL | completed | Phase 3 | 421 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03072771 | Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 1 | 14 | Washington University School of MedicineOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03255018 | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2023 | clinicaltrials |
| NCT01523223 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | completed | Phase 1 | 16 | Robert LowskyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04812691 | CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma | completed | Phase 1 | 12 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02617485 | MabionCD20 Compared to MabThera in Lymphoma Patients(MADILYM) | completed | Phase 3 | 143 | Mabion SAINDUSTRY | 7 | Oct 25, 2023 | clinicaltrials |
| NCT02399085 | Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL(L-MIND) | completed | Phase 2 | 81 | MorphoSys AGINDUSTRY | 10 | Oct 23, 2023 | clinicaltrials |
| NCT05338892 | Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma(ORCHID) | completed | — | 595 | Regeneron PharmaceuticalsINDUSTRY | 4 | Oct 19, 2023 | clinicaltrials |
| NCT04928573 | Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab | completed | — | 27 | Libbs Farmacêutica LTDAINDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT01431209 | Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant | completed | Phase 2 | 71 | University of NebraskaOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT02874404 | TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 13 | University of NebraskaOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT01000753 | Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma | completed | — | 174 | Children's Oncology GroupNETWORK | 4 | Oct 3, 2023 | clinicaltrials |
| NCT03309878 | Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04409314 | Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy | completed | — | 23 | University of California, San FranciscoOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT02576990 | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) | completed | Phase 2 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2023 | clinicaltrials |
| NCT02226965 | PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) | completed | Phase 2 | 45 | Sierra Oncology LLC - a GSK companyINDUSTRY | 2 | Jun 29, 2023 | clinicaltrials |
| NCT05918809 | Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings | completed | — | 1,031 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05130489 | CAR T Cell Therapy Related Cardiovascular Outcomes(CARTCO) | completed | — | 150 | University College London HospitalsOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT03677128 | Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment | completed | N/A | 75 | Duke UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT02431988 | Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation(COBALT) | completed | Phase 1 | 10 | University College, LondonOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT01092182 | Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 194 | National Cancer Institute (NCI)NIH | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04354402 | Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL | completed | — | 25 | SymBio PharmaceuticalsINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT01238692 | A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) | completed | Phase 2 | 42 | Sarit AssoulineOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04323657 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 6 | TCR2 TherapeuticsINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT00644189 | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT03019640 | Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03305445 | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL | completed | Phase 1 | 6 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 15, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 20, 2024source: clinicaltrials